News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Ethical approval for LCT’s NTCELL® Phase I trial

Living Cell Technologies Limited
Company Announcement

Ethical approval for LCT’s NTCELL® Phase I trial

16 November 2012: Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) has received ethical approval from the New Zealand Ministry of Health’s Health and Disability Ethics Committee to proceed with Phase I clinical trials of NTCELL® for Parkinson’s disease.
"We are extremely pleased to have received ethical approval in such an efficient timeframe," says Dr Andrea Grant, Chief Executive of LCT. "It means that LCT is still on track to commence NTCELL’s first in-human trials in Q1 2013.
LCT received regulatory authorisation from Medsafe to proceed with trials in October.

– Ends –

For further information: www.lctglobal.com

About Living Cell Technologies
Living Cell Technologies (LCT) leads the world in developing cell-based therapeutics to treat diseases with high unmet clinical need. Its proprietary cell encapsulation technology IMMUPEL™ allows for cell transplantation without the need for immunosuppressant drugs.
LCT’s lead therapeutic candidate DIABECELL® is indicated for the treatment of patients with type 1 diabetes, especially those suffering from life threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. DIABECELL is currently in Phase II clinical trials in both New Zealand and Argentina.
In 2011, LCT formed a partnership with Otsuka Pharmaceutical Factory Inc (OPF) in which the joint venture Diatranz Otsuka Limited (NZ) was established. Valued at A$50m on formation, LCT vested the DIABECELL product and associated IP into the JV, while OPF vested A$25m to fund the final phase of development of DIABECELL through to market approval. Both LCT and OPF are 50:50 shareholders in the current and future value generated by DIABECELL and the associated IP.
LCT has also developed NTCELL®, a choroid plexus cell product, to treat neurodegenerative diseases such as Parkinson's disease and stroke. NTCELL’s trial results indicate potential for protecting, repairing and possibly regenerating brain tissue which would otherwise die.
LCT is incorporated in Australia. Research and development, operations and manufacturing facilities are based in New Zealand.

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Fringe Review: Rossum’s Universal Robots

Written in 1920 by Karel Capek in a newly independent Czechoslovakia, its prophetic tale of artificial intelligence, automata and human morality was initially a big hit, but it then vanished from view, in New Zealand at least, before being revived in Hamilton last year. More>>

SELECT FRINGE SHOWS:

Pictures Of Media: Call For Photographs For Reimagining Journalism

In August this year Freerange Press is launching its next big book. This time we are gathering the best writers and thinkers in the country to look at the changing media landscape in New Zealand. To illuminate and give voice to the writing we want to include around 25 excellent photos. We want these photos to document the different aspects of how journalism is made, how it used to be, and how it is changing. More>>

Safer Internet Day: Keeping Safe Online More Important Than Ever

Tuesday 9 February marks Safer Internet Day. Safer Internet Day is designed to create awareness about the importance of Internet safety and encourages positive use of technology - with a strong focus on young people. More>>

ALSO:

We Have The Technology: Zephyrometer Up And Moving

“The needle’s stoppers had to be repaired because of the extra impact caused by the balance not being correct. We also added an extra 300kgs counter-balance – made from zinc coated steel triangle plates. These adjustments will now stop it bending low over the road in high winds.” More>>

ALSO:

Waitangi Day: Treaty Of Waitangi - Found In Translation

To celebrate the Society of Translators and Interpreters's 30th anniversary, over 90 translators will work together to translate the English and Māori versions of the Treaty of Waitangi into 30 languages... More>>

ALSO:

Northland Development: Trust Applauds $4m Government Funding For Art Centre

Today's announcement of central government support, made by Minister of Economic Development Steven Joyce, provides a key step forward in funding for Whangarei’s Hundertwasser Art Centre & Wairau Maori Art Gallery. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news